ClearPoint Neuro reports Q4 rev $4.3M (+15% YoY); FY2021 rev record $16.3M (+27% YoY); 2022 guidance $20-22M

ClearPoint Neuro, Inc.

2022-FY EPS reported -$0.69 revenue$16,299,000

Q4 2021 revenue $4.3M, up 15% YoY; functional neurosurgery products $2.1M (+37%), biologics/drug delivery $1.7M (+10%).
Full-year 2021 record revenue $16.3M (+27% YoY) and record case volume 929 (+36% YoY), within initial guidance of $16-17.5M.
Cash and equivalents $54.1M at year-end; management states no need for additional capital in 2022.
2022 revenue guidance $20-22M, representing growth of 23-35% YoY; COVID variant risk cited as key factor.
Earnings call scheduled for March 1, 2022 after market close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.